SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sage Therapeutics, Inc. (NASDAQ: SAGE) focused on whether Sage Therapeutics and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
Read more at prnewswire.comhello world
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
